Akèy › Limfom selil mantèl › Kansas
Etid klinik pou Limfom selil mantèl nan Kansas
7 etid pou Limfom selil mantèl ap chèche patisipan nan sit nan Kansas.
Vil nan Kansas
Tèks ofisyèl etid la (Anglè)
Testing Continuous Versus Intermittent Treatment With the Study Drug Zanubrutinib for Older Patients With Previously Untreated Mantle Cell Lymphoma
- HaysMed, Hays
- University of Kansas Cancer Center, Kansas City
- Lawrence Memorial Hospital, Lawrence
- ak 6 plis
Ap rekriteFaz 3
Laj 60 ak plis · Tout sèks · Mizajou Oct 2, 2026 · NCT05976763A Study to Investigate the Safety of Novel Dose Ramp-up Schedule(s) When Initiating Sonrotoclax in Participants Treated for Blood Cancers.
- The University of Kansas Cancer Center, Westwood
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Sep 28, 2026 · NCT06697184A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 )
- University of Kansas Cancer Center, Kansas City
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Sep 22, 2026 · NCT07101328DALY II USA/ MB-CART2019.1 for DLBCL
- University of Kansas Cancer Center, Westwood
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Jul 13, 2026 · NCT04792489SynKIR-310 for Relapsed/Refractory B-NHL
- The University of Kansas Cancer Center, Fairway
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Apr 14, 2026 · NCT06544265BAFFR-targeting CAR T Cells for Patients With Relapsed or Refractory B-NHL
- University of Kansas Hospital, Kansas City
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Nov 20, 2025 · NCT05370430A Safety and Efficacy Study Evaluating CTX112 in Subjects With Relapsed or Refractory B-Cell Malignancies
- University of Kansas, Westwood
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Nov 14, 2025 · NCT05643742Sous ClinicalTrials.gov, done yo ranmase Oct 5, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.